FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease

Rhea-AI Summary

FibroBiologics (Nasdaq:FBLG) announced that IP Australia has accepted Australian Patent Application No. 2020368344 covering the use of cannabidiol (CBD) as an adjuvant to fibroblast-based cell therapy for the treatment of degenerative disc disease. The application describes methods of co-administering CBD with therapeutically effective fibroblast cells, including fibroblasts differentiated into notochord cells or chondrocytes, to support regeneration of the nucleus pulposus.

The claims also include using CBD to enhance fibroblast regenerative activity, such as boosting production of growth factors like IGF-1 and EGF-1. According to FibroBiologics, the acceptance strengthens its intellectual property position in disc degeneration, adding to its portfolio of 270+ issued and pending patents worldwide.

Positive

• Australian patent application accepted for CBD adjuvant fibroblast therapy in degenerative disc disease
• Claims cover multiple administration routes for cannabidiol, including systemic, transdermal, and intradiscal delivery
• IP strengthened in disc degeneration, cited as a core clinical pathway in the company’s portfolio
• Broad patent scope includes fibroblasts differentiated into notochord cells or chondrocytes and growth factor enhancement
• Extensive IP estate with 270+ issued and pending patents across multiple clinical pathways

Negative

• None.

Market Context

Recent FBLG patent-related announcements were followed by 5.1% and 5.6% 24-hour reactions, providing...

Analysis

Recent FBLG patent-related announcements were followed by 5.1% and 5.6% 24-hour reactions, providing a historical comparison for this Australian acceptance. The active S-3 resale registration for 12,530,613 shares adds a separate market-structure risk to monitor.

Key Figures

Patent portfolio: 270+ patents Affected population: hundreds of millions of people

2 metrics

Patent portfolio 270+ patents U.S. and internationally issued and pending

Affected population hundreds of millions of people Degenerative disc disease worldwide

Historical Context

5 past events · Latest: Aug 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 18	Preclinical joint data	Positive	+11.8%	Preclinical cartilage repair reported after a single injection in induced joint defects.
Aug 11	U.S. patent grant	Positive	+5.1%	Patent covered fibroblast use to enhance transplanted islet survival and function.
Aug 05	European patent grant	Positive	+5.6%	European patent covered Sox9-based gene therapy for cartilage regeneration.
Jul 31	Q2 earnings report	Positive	+12.9%	Quarterly results accompanied first patient dosing in a Phase 1/2 wound-care trial.
Jul 09	Board appointment	Positive	+5.4%	Kathleen Rubins was appointed as a Class III director and committee member.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All five selected prior news events were followed by positive 24-hour reactions, indicating consistent historical alignment with favorable announcements.

Key Terms

cannabidiol, apoptosis, extracellular matrix, nucleus pulposus, +2 more

6 terms

cannabidiol medical

"use of cannabidiol in combination with fibroblast-based cell therapy"

Cannabidiol (CBD) is a natural compound found in cannabis and hemp plants that does not produce a “high.” Investors watch CBD because it is the active ingredient in many health, wellness, and consumer products, and its value depends on shifting rules, clinical evidence, product approvals, and consumer demand—much like a key ingredient in a popular food or drug that determines shelf placement, pricing, and sales potential.

apoptosis medical

"intended to reduce apoptosis of disc cells"

Apoptosis is a controlled, built‑in process where cells deliberately shut down and are safely removed, like a person retiring and clearing out their belongings so the house stays orderly. Investors care because many drugs and diagnostics target or measure this process: how well a therapy triggers or avoids apoptosis can determine clinical trial success, safety profiles, regulatory approval, and ultimately a company’s valuation.

extracellular matrix medical

"remodel the extracellular matrix"

A network of proteins and other molecules that sits outside cells and gives tissues their shape, strength and a medium for cells to send signals and move — like the scaffolding and wiring inside a building. Investors care because changes to this matrix play a major role in diseases, wound healing and tissue repair, making it a common target for drugs, medical devices and diagnostics that can drive regulatory decisions and commercial value.

nucleus pulposus medical

"cells of the nucleus pulposus, the gel-like core of the disc"

The nucleus pulposus is the soft, gel-like center of an intervertebral disc that sits between the bones of the spine and helps absorb shocks and distribute pressure when the body moves. Investors encounter the term because it is a common target in medical research, devices, and therapies for back pain and spinal disorders — developments affecting market opportunities, regulatory review, and potential commercial products in orthopedics and biotechnology.

chondrocytes medical

"fibroblasts differentiated into notochord cells or chondrocytes"

Specialized cells that make and maintain cartilage, the flexible tissue that cushions joints and shapes parts like the nose and ear. Think of them as the builders and caretakers of a rubbery cushion: they produce the proteins and sugars that form cartilage’s structure and repair. They matter to investors because therapies, drugs, and medical devices targeting cartilage health or regenerative medicine often focus on influencing chondrocyte function or survival.

igf-1 medical

"production of growth factors such as IGF-1 and EGF-1"

A naturally occurring protein hormone that helps cells grow, survive and repair, acting like a biological 'fertilizer' for tissues. Investors watch IGF-1 because drugs that raise, block, or mimic it can affect treatments for growth disorders, metabolic diseases and certain cancers, making it a common target in clinical trials; trial results, safety concerns or regulatory decisions tied to IGF-1 activity can materially change a healthcare company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc disease

HOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the acceptance by IP Australia of Australian Patent Application No. 2020368344, entitled "Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease." The accepted application describes methods of treating degenerative disc disease by administering cannabidiol together with a therapeutically effective amount of fibroblast cells, as well as methods of using cannabidiol to augment the regenerative activity of fibroblasts.

Degenerative disc disease is one of the most common causes of chronic back and neck pain, affecting hundreds of millions of people worldwide. The condition develops as the intervertebral discs that cushion the spine gradually lose hydration, structure, and cellular vitality, often leading to pain, reduced mobility, and diminished quality of life. Current treatment options are largely limited to pain management, physical therapy, and invasive surgical procedures such as spinal fusion, none of which restore the underlying health of the disc.

Fibroblasts are the most common cell type in connective tissue and are increasingly recognized for their regenerative and immunomodulatory properties. Beyond their traditional structural role, fibroblasts secrete growth factors, remodel the extracellular matrix, and modulate immune responses, characteristics that make them attractive candidates for treating degenerative conditions of the spine.

The newly accepted patent application addresses this unmet need by combining two complementary approaches. Fibroblast-based cell therapy, including fibroblasts differentiated into notochord cells or chondrocytes, is designed to replenish and support the cells of the nucleus pulposus, the gel-like core of the disc. Cannabidiol, administered systemically, transdermally, or directly into the disc, is intended to reduce apoptosis of disc cells and create a more favorable environment for regeneration. The claims also cover the use of cannabidiol to enhance the regenerative activity of fibroblasts, including augmenting their production of growth factors such as IGF-1 and EGF-1.

"Degenerative disc disease affects an enormous number of people, and the treatments available today address symptoms rather than the disease itself," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. "Pairing cannabidiol with our fibroblast-based cell therapy is designed to protect the cells of the disc while promoting regeneration. This acceptance strengthens our intellectual property position in disc degeneration, one of the core clinical pathways in our portfolio."

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, FibroBiologics' research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-australian-patent-accepted-for-cannabidiol-adjuvant-therapy-for-the-treatment-of-degenerative-disc-disease-302855757.html

SOURCE FibroBiologics, Inc.

FAQ

What did FibroBiologics (FBLG) announce on August 20, 2026 about its Australian patent?

FibroBiologics announced that IP Australia accepted its patent application 2020368344 for cannabidiol adjuvant therapy in degenerative disc disease. According to FibroBiologics, the application covers combining cannabidiol with fibroblast-based cell therapy to support disc regeneration and enhance fibroblast regenerative activity.

What does FibroBiologics’ Australian patent application 2020368344 cover for degenerative disc disease?

The accepted application covers treating degenerative disc disease by administering cannabidiol with therapeutic fibroblast cells. According to FibroBiologics, it includes fibroblasts differentiated into notochord cells or chondrocytes and using cannabidiol to boost fibroblast growth factor production like IGF-1 and EGF-1.

How does cannabidiol work with FibroBiologics’ fibroblast-based therapy according to the FBLG patent?

According to FibroBiologics, cannabidiol is intended to reduce apoptosis of disc cells and create a favorable regenerative environment. Combined with fibroblast-based cell therapy, it aims to support nucleus pulposus cells and enhance fibroblast-driven production of regenerative growth factors in the disc.

Why is the Australian patent acceptance important for FibroBiologics (FBLG) investors?

The acceptance strengthens FibroBiologics’ intellectual property position in disc degeneration, described as a core clinical pathway. According to FibroBiologics, it adds to an estate of 270+ issued and pending patents, potentially reinforcing competitive barriers around its fibroblast-based spine therapies.

What administration routes for cannabidiol are described in FibroBiologics’ degenerative disc disease patent?

According to FibroBiologics, cannabidiol can be administered systemically, transdermally, or directly into the disc. These routes are described as ways to reduce apoptosis of disc cells and help create conditions that may support regeneration when used with fibroblast-based cell therapy.

How does FibroBiologics position its fibroblast platform beyond degenerative disc disease?

FibroBiologics reports a pipeline using fibroblast cells and fibroblast-derived materials across multiple chronic diseases. According to FibroBiologics, its 270+ patents and applications span wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer clinical pathways.